A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026 on ClinicalTrials.gov · last registry update 2026-09-21

An unusually large phase 4: 200 participants, more than double the 75 typical for the stage. Due to report August 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 200
Started: 2025-03-06
Primary completion: 2027-08 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-21	Reporting date moved	2027-11 → 2027-08 3 months earlier
2026-09-21	Status changed	RECRUITING → ACTIVE_NOT_RECRUITING

Primary outcome

Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy

Conditions studied

Psoriatic Arthritis · Overweight or Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.